COVID-19 vaccines continue to be administered around the world every day, but a new one might be here to speed up the process.
Johnson & Johnson announced Friday their new "single-shot" vaccine has shown positive results, and they intend to file for U.S. Emergency Use Authorization in early February.
These topline results with a single-shot COVID-19 vaccine candidate represent a promising moment.
Paul Stoffels, M.D., Johnson & Johnson
The phase 3 trial of the vaccine posted what doctors are calling promising results, as it was 85% effective in preventing severe disease, and 66% effective overall in preventing moderate to severe COVID-19 across all regions studied.
"The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunization, is a critical component of the global public health response," said Stoffels.
Johnson & Johnson says the vaccine's safety profile matches others using the same technology, with 9% of volunteers developing a fever.
Editor's Note: The CDC has a robust website with all the latest information on the vaccine and can answer any questions you may have. Click here for more information.